Survival and late toxicities following concurrent chemo-radiotherapy for locally advanced stage III non-small cell lung cancer: findings of a 10-year Australian single centre experience with long term clinical follow up | Zendy

M. Nazim Abbas | Zendy; Adeola O. Ayoola | Zendy; Sunita Padman | Zendy; Rajiv Kumar | Zendy; John Leung | Zendy; Shahid Ullah | Zendy; Bogda Koczwara | Zendy; Shawgi Sukumaran | Zendy; Ganessan Kichenadasse | Zendy; Amitesh Roy | Zendy; Alison Richards | Zendy; Jeffrey J. Bowden | Zendy; Christos S. Karapetis | Zendy

Open Access

Survival and late toxicities following concurrent chemo-radiotherapy for locally advanced stage III non-small cell lung cancer: findings of a 10-year Australian single centre experience with long term clinical follow up

Author(s) -

M. Nazim Abbas,

Adeola O. Ayoola,

Sunita Padman,

Rajiv Kumar,

John Leung,

Shahid Ullah,

Bogda Koczwara,

Shawgi Sukumaran,

Ganessan Kichenadasse,

Amitesh Roy,

Alison Richards,

Jeffrey J. Bowden,

Christos S. Karapetis

Publication year - 2019

Publication title -

journal of thoracic disease

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.682

H-Index - 60

eISSN - 2077-6624

pISSN - 2072-1439

DOI - 10.21037/jtd.2019.09.56

Subject(s) - medicine , stage (stratigraphy) , radiation therapy , single stage , lung cancer , oncology , cancer , lung , paleontology , biology , engineering , aerospace engineering

The preferred management of patients with unresectable locally advanced non-small cell lung cancer (LA-NSCLC) is concurrent chemo-radiotherapy (CRT). Acute CRT-related toxicities are well defined, however, less is known about late toxicities. The aim of the study was to examine the outcomes and late toxicities in Stage III NSCLC treated with CRT.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research